PNH Clinical Trials

15 recruitingLast updated: May 11, 2026

There are 15 actively recruiting pnh clinical trials across 17 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Tianjin, Tianjin Municipality, China, London, United Kingdom, Paris, France. Updated daily from ClinicalTrials.gov.


PNH Trials at a Glance

15 actively recruiting trials for pnh are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Tianjin, London, and Paris. Lead sponsors running pnh studies include Alexion Pharmaceuticals, Inc., Novartis Pharmaceuticals, and Wuhan Createrna Science and Technology Co., Ltd.

Browse pnh trials by phase

Treatments under study

About PNH Clinical Trials

Looking for clinical trials for PNH? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PNH trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PNH clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria, PNHSevere Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1Phase 2

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals50 enrolled7 locationsNCT07229235
Recruiting
Phase 3

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967
Recruiting
Phase 1

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

Paroxysmal Nocturnal Hemoglobinuria, PNHComplement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd.88 enrolled1 locationNCT07462780
Recruiting
Phase 1Phase 2

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled7 locationsNCT07187401
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 3

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

PNHExtravascular HemolysisParoxysmal nocturnal hemoglobinuria
Alexion Pharmaceuticals, Inc.6 enrolled4 locationsNCT06449001
Recruiting
Phase 1

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH - Paroxysmal Nocturnal Hemoglobinuria
Shanghai Lanyi Therapeutics Co., Ltd.24 enrolled2 locationsNCT07256301
Recruiting
Phase 1

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

Paroxysmal Nocturnal Hemoglobinuria, PNH
Haisco Pharmaceutical Group Co., Ltd.24 enrolled1 locationNCT07152288
Recruiting
Phase 2

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria, PNHParoxysmal Hemoglobinuria
Apellis Pharmaceuticals, Inc.12 enrolled12 locationsNCT04901936
Recruiting
Phase 2

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH - Paroxysmal Nocturnal Hemoglobinuria
S-INFINITY Pharmaceuticals Co., Ltd24 enrolled1 locationNCT06978699
Recruiting
Phase 3

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Paroxysmal nocturnal haemoglobinuria (PNH)
Wuhan Createrna Science and Technology Co., Ltd66 enrolled2 locationsNCT06932744
Recruiting
Phase 2Phase 3

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH
Wuhan Createrna Science and Technology Co., Ltd120 enrolled1 locationNCT06933914